Mechanisms of resistance to ErbB-targeted cancer therapeutics.


The ErbB receptors, such as EGFR, have been intensely pursued as targets for cancer therapeutics. However, a large percentage of patients who are initially responsive to ErbB-targeted therapies experience tumor recurrence and become refractory to therapy. In this issue of the JCI, Guix et al. demonstrate that downregulation of IGF-binding protein 3 (IGFBP-3… (More)
DOI: 10.1172/JCI36260

1 Figure or Table


  • Presentations referencing similar topics